Table 2.
Levels of SARS-CoV-2-S-Abs in BNT162b2 (tozinameran)-vaccinated patients on dialysis at different time points
| All patients | Haemodialysis | Peritoneal dialysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Time point | Mean (U/mL) | SD | Resp., n | Mean (U/mL) | SD | Resp., n | Mean (U/mL) | SD | Resp., n | P-valuea |
| After first vaccine dose | 43.9 | 211.4 | 34/81 | 15.4 | 29.5 | 30/75 | 311.6 | 678.9 | 4/6 | .4892 |
| 4 weeks after complete vaccination | 1192.1 | 1873.1 | 144/165 | 1140.0 | 1950.7 | 121/141 | 1473.0 | 1382.6 | 23/24 | .0081 |
| 10–12 weeks after complete vaccination | 396.2 | 928.0 | 164/181 | 416.5 | 416.5 | 144/160 | 244.9 | 285.1 | 20/21 | .5674 |
| Prior to booster vaccination | 261.4 | 426.5 | 147/166 | 271.1 | 436.9 | 131/150 | 230.2 | 369.1 | 16/16 | .2257 |
| 4 weeks after booster vaccination | 23 119.8 | 29 603.4 | 148/148 | 23 982.8 | 30 597.1 | 134/134 | 14 859.4 | 15 830.4 | 14/14 | .3577 |
Patients were vaccinated with a full dose of mRNA-1273 (elasomeran) within 6 months after their first immunization. Resp., responder; SD, standard deviation.
aComparison of mean SARS-CoV-2-S-Ab concentrations between patients on haemodialysis versus peritoneal dialysis for each time point.